 | Up a level |
Janjigian, Yelena Y., Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Shen, Lin, Wyrwicz, Lucjan 
ORCID: 0000-0003-0808-6892, Yamaguchi, Kensei, Skoczylas, Tomasz ORCID: 0000-0002-1276-3828, Bragagnoli, Arinilda Campos, Liu, Tianshu, Schenker, Michael ORCID: 0000-0003-2645-6391, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V., Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M., Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun and Ajani, Jaffer A.
(2021).
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet, 398 (10294).
S. 27 - 41.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X
Kelly, Ronan J., Ajani, Jaffer A., Kuzdzal, Jaroslaw, Zander, Thomas, Van Cutsem, Eric, Piessen, Guillaume, Mendez, Guillermo, Feliciano, Josephine, Motoyama, Satoru, Lievre, Astrid, Uronis, Hope, Elimova, Elena, Grootscholten, Cecile, Geboes, Karen, Zafar, Syed, Snow, Stephanie ORCID: 0000-0003-3847-0289, Ko, Andrew H., Feeney, Kynan, Schenker, Michael ORCID: 0000-0003-2645-6391, Kocon, Piotr, Zhang, Jenny, Zhu, Lili, Lei, Ming, Singh, Prianka, Kondo, Kaoru, Cleary, James M. and Moehler, Markus
(2021).
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N. Engl. J. Med., 384 (13).
S. 1191 - 1204.
WALTHAM:
MASSACHUSETTS MEDICAL SOC.
ISSN 1533-4406
Kelly, Ronan Joseph, Ajani, Jaffer A., Kuzdzal, Jaroslaw, Zander, Thomas, Van Cutsem, Eric, Piessen, Guillaume, Mendez, Guillermo, Feliciano, Josephine Louella, Motoyama, Satoru, Lievre, Astrid, Uronis, Hope Elizabeth, Elimova, Elena, Grootscholten, Cecile, Geboes, Karen Paula, Zhang, Jenny, Soleymani, Samira, Lei, Ming, Singh, Prianka, Cleary, James M. and Moehler, Markus H. (2021). Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Lutz, Manfred P., Zalcberg, John R., Ducreux, Michel ORCID: 0000-0001-8649-7449, Ajani, Jaffer A., Allum, William, Aust, Daniela, Bang, Yung-Jue, Cascinu, Stefano ORCID: 0000-0003-2215-0731, Hoelscher, Arnulf, Jankowski, Janusz ORCID: 0000-0003-2130-9181, Jansen, Edwin P. M., Kisslich, Ralf, Lordick, Florian, Mariette, Christophe, Moehler, Markus, Oyama, Tsuneo, Roth, Arnaud, Rueschoff, Josef, Ruhstaller, Thomas, Seruca, Raquel ORCID: 0000-0002-8851-4166, Stahl, Michael, Sterzing, Florian, van Cutsem, Eric, van der Gaast, Ate, van Lanschot, Jan, Ychou, Marc ORCID: 0000-0001-7378-9469 and Otto, Florian
(2012).
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer.
Eur. J. Cancer, 48 (16).
S. 2941 - 2954.
OXFORD:
ELSEVIER SCI LTD.
ISSN 1879-0852
Shitara, Kohei, Ajani, Jaffer A., Moehler, Markus, Garrido, Marcelo, Gallardo, Carlos, Shen, Lin, Yamaguchi, Kensei, Wyrwicz, Lucjan, Skoczylas, Tomasz ORCID: 0000-0002-1276-3828, Bragagnoli, Arinilda Campos, Liu, Tianshu, Tehfe, Mustapha, Elimova, Elena, Bruges, Ricardo, Zander, Thomas, de Azevedo, Sergio, Kowalyszyn, Ruben, Pazo-Cid, Roberto, Schenker, Michael ORCID: 0000-0003-2645-6391, Cleary, James M., Yanez, Patricio, Feeney, Kynan, Karamouzis, Michalis, V, Poulart, Valerie, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun and Janjigian, Yelena Y.
(2022).
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature, 603 (7903).
S. 942 - 963.
BERLIN:
NATURE PORTFOLIO.
ISSN 1476-4687